S-Bank Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

S-Bank Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,460	Closed	-$133K	–	181
2025 Q3	$133K	Sell	2,460 -32	-1%	-$1.83K	0.02%	187
2025 Q2	$137K	Sell	2,492 -418	-14%	-$24.6K	0.02%	187
2025 Q1	$206K	Buy	+2,910	New	+$196K	0.04%	155

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

S-Bank Fund Management's BMRN Position: Q4 2025 in Review

S-Bank Fund Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 2,460 shares — an estimated $133K sold.

S-Bank Fund Management first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $206K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

S-Bank Fund Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
S-Bank Fund Management sold 2,460 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $133K.
S-Bank Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
S-Bank Fund Management's BioMarin Pharmaceuticals position peaked at $206K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on S-Bank Fund Management's 13F filing for Q4 2025, filed 3 Feb 2026.